Detalhe da pesquisa
1.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
N Engl J Med
; 385(24): 2219-2229, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34879448
2.
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
J Am Acad Dermatol
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38556093
3.
Cedirogant in adults with psoriasis: a phase 2, randomized, placebo-controlled clinical trial.
Clin Exp Dermatol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38699939
4.
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Lancet
; 400(10348): 273-282, 2022 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35871814
5.
Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Br J Dermatol
; 189(5): 540-552, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37488811
6.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Lancet
; 397(10290): 2151-2168, 2021 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34023008
7.
Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
Skin Therapy Lett
; 27(6): 1-5, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469536
8.
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
J Allergy Clin Immunol
; 145(3): 877-884, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31786154
9.
Érythème polymorphe majeur associé à une infection au SRAS-CoV-2 chez un patient à la peau foncée.
CMAJ
; 196(2): E61-E62, 2024 Jan 21.
Artigo
em Francês
| MEDLINE | ID: mdl-38253367
10.
Current Practices of Allergy Testing in Adults With Atopic Dermatitis in Canada: A National Survey.
J Cutan Med Surg
; : 12034754241239260, 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504147
11.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Lancet
; 389(10086): 2287-2303, 2017 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28478972
12.
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
Br J Dermatol
; 188(6): 810-812, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36890712
13.
Erythema multiforme major associated with SARS-CoV-2 infection in a patient with skin of colour.
CMAJ
; 195(46): E1581-E1582, 2023 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38011927
14.
Dupilumab: A review of its use in the treatment of atopic dermatitis.
J Am Acad Dermatol
; 78(3 Suppl 1): S28-S36, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29471919
15.
Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: A Canadian perspective.
J Am Acad Dermatol
; 89(2): 372-375, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37074241
16.
Proactive Topical Maintenance Treatment of Psoriasis: Subanalysis of Canadian Patients in the Phase III PSO-LONG Trial.
J Cutan Med Surg
; 27(1): 63-64, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36437761
17.
Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
J Drugs Dermatol
; 14(1): 33-40, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25607906
18.
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor).
Dermatol Ther (Heidelb)
; 14(2): 441-451, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38332436
19.
Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
J Dermatolog Treat
; 35(1): 2324833, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38735650
20.
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
Dermatol Ther (Heidelb)
; 14(5): 1145-1160, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700646